Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerAI sign LanguageOpen
VIPCreated with Sketch.

Fight-205: Phase Ii Study Of First-Line Pemigatinib (Pemi) Plus Pembrolizumab (Pembro) Versus Pemi Alone Versus Standard Of Care (Soc) For Cisplatin (Cis)-Ineligible Urothelial Carcinoma (Uc) With Fgfr3 Mutation Or Rearrangement

Matt D. Galsky, Thomas Powles,Robert Dreicer,Hiroshi Kitamura,Ekatherine Asatiani, Jason Howe,Huiling Zhen,Natalia Oliveira, Andrea Necchi

JOURNAL OF CLINICAL ONCOLOGY（2020）

Cited 4|Views4
No score
Abstract
TPS592Background: Fibroblast growth factor receptor (FGFR) 3 gene alterations (GAs) are involved in UC pathogenesis. Pts with metastatic UC and FGFR3 GAs express low programmed cell death ligand 1 ...
More
Translated text
Key words
pembrolizumab,cisplatin,pemigatinib,pembrolizumab,first-line
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined